Evolution of the Average Target: Pfizer Inc.

Evolution of the Target Price: Pfizer Inc.

Changes in Analyst Recommendations: Pfizer Inc.

3ce9a0d0a30.KteFMFXC5oDIjDoFpt6wsV45cMRMwDl541Yu4n4SjsA.e7XmeSL3lO38yGJ06LKE3zd2O7cf8XxPhj9loTF0xItmkeB6Fquiw_j1Ag~e40a430f02eadfedbd92552e67ebb4fa
06-01 PFIZER INC : Jefferies remains its Buy rating ZD
06-01 PFIZER INC : JP Morgan remains Neutral ZD
05-28 PFIZER INC : Barclays reiterates its Sell rating ZD
05-18 Daiwa Securities Adjusts Price Target on Pfizer to $28 From $27, Maintains Neutral Rating MT
05-06 PFIZER INC : DZ Bank reiterates its Buy rating ZD
05-06 PFIZER INC : UBS remains Neutral ZD
05-06 PFIZER INC : Jefferies reaffirms its Buy rating ZD
05-06 Leerink Partners Adjusts Price Target on Pfizer to $28 From $26 MT
05-05 PFIZER INC : JP Morgan reaffirms its Neutral rating ZD
04-28 Citigroup Lifts Price Target on Pfizer to $27 From $26, Maintains Neutral Rating MT
04-28 Jefferies Adjusts Price Target on Pfizer to $35 From $34, Maintains Buy Rating MT
04-23 Rothschild & Co Redburn Adjusts Price Target on Pfizer to $24 From $25, Maintains Neutral Rating MT
04-20 Pfizer's Upcoming Tafamidis Bench Trial Shows Asymmetric Upside, RBC Capital Markets Says MT
04-16 CICC Initiates Pfizer at Outperform With $33 Price Target MT
04-13 UBS Raises Price Target on Pfizer to $27 From $25, Maintains Neutral Rating MT
04-13 BMO Capital Adjusts Price Target on Pfizer to $34 From $30, Maintains Outperform Rating MT
04-10 PFIZER INC : Gets a Neutral rating from JP Morgan ZD
04-09 Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says MT
04-09 BofA Adjusts Price Target on Pfizer to $26 From $27, Maintains Neutral Rating MT
03-24 PFIZER INC : Jefferies keeps its Buy rating ZD
03-24 Guggenheim Adjusts Pfizer's PT to $36 From $35, Keeps Buy Rating MT
03-17 HSBC Adjusts Price Target on Pfizer to $32 From $29, Maintains Buy Rating MT
03-10 PFIZER INC : UBS is Neutral ZD
03-09 Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB… Zonebourse
02-20 Barclays Initiates Coverage on Pfizer With Underweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+12.09%
+7.4%
+8.63%
+11.58%
+10.29%
+19.45%
+4.53%
+9.84%
+0.76%
+22.2%
Average +10.68%
Weighted average by Cap. +9.73%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
26.04USD
Average target price
29.19USD
Spread / Average Target
+12.09%
High Price Target
36.00USD
Spread / Highest target
+38.25%
Low Price Target
24.00USD
Spread / Lowest Target
-7.83%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

JPMORGAN Chris Schott
JEFFERIES Akash Tewari
BARCLAYS Emily Field
Daiwa Securities
Leerink Partners
DZ BANK Elmar Kraus
UBS
Jefferies & Co.
Citigroup
Rothschild & Co Redburn
CICC Research
BMO Capital
BofA Securities
Guggenheim
HSBC
GOLDMAN SACHS Asad Haider
Wolfe Research
Cantor Fitzgerald
BERENBERG Luisa Hector
Morgan Stanley
Scotiabank
CMB International
TD Cowen
BERNSTEIN RESEARCH Justin Smith
Berenberg Bank
Redburn Atlantic
Bernstein
Wells Fargo Securities
DA Davidson
Argus
Truist Securities
Redburn
JPMorgan Chase
SVB Securities LLC
Credit Suisse
Atlantic Equities
Mizuho Securities
Atlantic Securities
SVB Leerink
Independent Research
RBC
RBC Capital Markets
J.P. Morgan Chase
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
26.04USD
Average target price
29.19USD
Spread / Average Target
+12.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PFE Stock
  4. Consensus Pfizer Inc.